Matrix-M
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Matrix-M
- DrugBank Accession Number
- DB16369
- Background
Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.1 This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Matrix-M1
- Matrix-M1 Adjuvant
- External IDs
- Matrix-M
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Matrix-M can enhance activated T-cell, B-cell, and antigen-presenting cell populations by inducing the influx of antigen-presenting cells.1 It can also enhance both B-cell immunity and T-cell immunity.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- YZ7P8Y8ECX
- CAS number
- Not Available
References
- General References
- Novavax: Novavax addresses urgent global public health needs with innovative technology [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Prevention Coronavirus (SARS-CoV) / Coronavirus Disease 2019 (COVID‑19) 1 3 Enrolling by Invitation Prevention Plasmodium Infections 1 2 Completed Prevention Respiratory Syncytial Virus (RSV) 1 2 Not Yet Recruiting Treatment Malaria caused by Plasmodium falciparum 1 2 Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) 1 1 Completed Prevention Ebola 1 1 Completed Prevention Matrix M / Plasmodium Infections 1 1 Completed Prevention Plasmodium Infections 1 1 Enrolling by Invitation Prevention Malaria caused by Plasmodium falciparum 1 1 Recruiting Treatment Malaria caused by Plasmodium falciparum 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 20, 2020 03:30 / Updated on December 20, 2020 03:42